Bimekizumab-treated patients with active psoriatic arthritis showed sustained achievement of minimal disease activity and remission: Up to 2-year results from two phase 3 studies

被引：0

作者：

Coates, L. C. ^{[1
,2
,3
]}

Kristensen, L. E. ^{[4
]}

Ogdie, A. ^{[5
]}

Tillett, W. ^{[6
,7
]}

Ink, B. ^{[8
]}

Goldammer, N. ^{[9
]}

Bajracharya, R. ^{[8
]}

Coarse, J. ^{[10
]}

Orbai, A. M. ^{[11
]}

机构：

[1] Nuffield Orthopaed Ctr, Oxford, England

[2] Univ Oxford, Oxford Univ Hosp NHS Trust, Oxford, England

[3] Oxford Biomed Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelea, Oxford, England

[4] Copenhagen Univ Hosp, Parker Inst Bispebjerg & Frederiksberg, Copenhagen, Denmark

[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[6] Royal Natl Hosp Rheumat Dis, Bath, Avon, England

[7] Univ Bath, Ctr Therapeut Innovat, Dept Life Sci, Bath, Avon, England

[8] UCB Pharma, Slough, Berks, England

[9] UCB Pharma, Monheim, Germany

[10] UCB Pharma, Morrisville, NY USA

[11] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IP 8

引用

页码：35S / 35S

页数：1